||||||||||NEXI-001 / NexImmune Enrollment closed, Trial completion date, Trial primary completion date: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT (clinicaltrials.gov) - Jan 16, 2024 P1/2, N=22, Active, not recruiting, Sponsor: NexImmune Inc. Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Oct 2022 --> Oct 2024
||||||||||NEXI-002 / NexImmune In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_858; P1/2 The AIM ACT platform is currently being used for generating T cell products for our current clinical trials, NEXI-001 (NCT04284228) and NEXI-002 (NCT04505813), and our pre-clinical development for HPV-associated malignancies. The findings support initiating Phase I trials of adoptive T cell therapy in solid tumors.